biotech
Kamada BioPharma Limited
Kamada BioPharma Limited at Fieldfisher LLP
Kamada BioPharma Limited is a biotech organization headquartered in GB. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and U
Company details
- Status
- Public
- HQ
- GB
- Programs
- 1
- Drugs
- 3
- Patents
- 0
KamadaAATInhaled008
Phase 3 · small molecule · Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.
KamadaAATInhaled008 for Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year. is a Phase 3 program (small_molecule) at Kamada BioPharma Limited at Fieldfisher LLP with 1 ClinicalTrials.gov record(s).
Internal code KamadaAATInhaled008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kamada BioPharma Limited at Fieldfisher LLP
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.
- Status
- active
- Trials
- 1